P20 Monitoring the uptake of hepatitis C: direct acting antiviral treatment in Australia

by B. Hajarizadeh, J. Grebely, G.V. Matthews, M. Martinello, G.J. Dore
Published 2017-08-01

O23 Characterisation of populations with hepatitis C to improve access to antiviral therapy programs: a population-based linkage study

by M. Alavi, J. Amin, J. Grebely, M.G. Law, N.Z. Janjua, M. Krajden, B. Hajarizadeh, J. George, G.V. Matthews, S. Larney, L. Degenhardt, G.J. Dore
Published 2017-08-01

P6 Phylogenetic clustering of recent hepatitis C virus infection between 2004 and 2015

by S.R. Bartlett, T. Applegate, B. Jacka, F. Lamoury, R. Bull, M. Danta, D. Bradshaw, A.R. Lloyd, M. Hellard, G.J. Dore, G.V. Matthews, J. Grebely
Published 2017-08-01

O5 Hepatitis C elimination in HIV/HCV co-infection through HCV treatment in primary care is feasible and highly effective

by J.S. Doyle, A.L. Bowring, J. Cutts, J. Roney, D.M. Iser, J. Sasadeusz, M. O’Reilly, C. Fairley, E. Gane, J. Hoy, G.V. Matthews, N. Medland, R. Moore, M. Prins, M. Stoové, B.K. Tee, M.E. Hellard
Published 2017-08-01

O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study

by J. Grebely, O. Dalgard, B. Conway, E. Cunningham, P. Bruggmann, B. Hajarizadeh, J. Amin, P. Marks, S. Quiene, T.L. Applegate, T. Swan, J. Byrne, M. Lacalamita, A. Dunlop, J. Bruneau, M.E. Hellard, G.V. Matthews, J. Powis, D. Shaw, M.C. Thurnheer, M. Weltman, I. Kronborg, C. Cooper, J.J. Feld, C. Fraser, A. Litwin, J. Dillon, P. Read, E. Gane, G.J. Dore
Published 2017-08-01